8044 Background: We previously reported that PDS of Pem and Erl (Pem 500 mg/m 2 IV on
day 1 and Erl 150 mg po QD on days 2-17 of a 21-day cycle) as 2 nd -line therapy has …

… Pharmacodynamic assays in skin To assess the pharmacodynamic effects of treatment
with an EGFR tyrosine kinase inhibitor, normal skin as a surrogate tissue was procured for …

… safety, pharmacokinetics, and pharmacodynamics and to … erlotinib in patients who failed
prior erlotinib treatment. In phase II, patients with prior response or stable disease with erlotinib …

… overcome acquired resistance to erlotinib in patients with lung … and erlotinib in patients with
acquired resistance to erlotinib, … of a trial combining erlotinib and cetuximab in patients with …

… future prospective study of PDS of pemetrexed and intercalated erlotinib as maintenance
or second-line therapy against new second-line standards might be warranted in patients with …

… In this study, the combination of erlotinib and sorafenib in patients with recurrent GBM
was intended to inhibit the EGFR and Ras signal transduction pathways, both of which are …

… NCA in this study, which is higher than predicted from preclinical studies and clinical
observations. Preliminary studies in animal models indicated that the oral BA of erlotinib is ∼77% …

… The S3 schedule did not achieve ≥33% of patients with … daily in a separate clinical study
(18), and erlotinib was already at the … and pharmacodynamic data from the monotherapy study …

… Several studies have reported the relationship between pharmacokinetics and
pharmacodynamics of erlotinib, 7 and some cases reported on the use of TDM in erlotinib. By …

… 14 skipping alterations.4, 5, 6 Herein we report the results from a phase I study combining
crizotinib with erlotinib in patients with advanced nonsquamous NSCLC (NCT00965731 ). …